Navigation Links
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
Date:4/21/2009

- Data on novel pro-apoptotic agent presented at the 100th Annual Meeting of the American Association for Cancer Research -

- University of Pennsylvania data on chemotherapy resistance patterns in neuroblastoma cell lines, highlighting AT-101's inhibition of Mcl-1, also presented -

MALVERN, Pa., April 21 /PRNewswire/ -- Ascenta Therapeutics announced today that the results of preclinical studies of its orally-active, small molecule, pro-apoptotic agent, AT-406, have been presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR), in Denver, Colorado (Abstract # 1917).

(Logo: http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO )

The studies demonstrated that AT-406 was active as a single agent in vitro in a number of cell lines, including breast cancer, lung cancer, pancreatic cancer, prostate cancer, and bladder cancer, and in several mouse xenograft cancer models. AT-406 also showed synergistic or additive effects when used together with tyrosine kinase inhibitors or chemotherapy in vitro in those cell lines.

"AT-406 is the second agent in our development pipeline to demonstrate broad anti-cancer activity in pre-clinical models, including synergy with other agents, by targeting a specific apoptotic pathway," said Mel Sorensen, MD, CEO of Ascenta Therapeutics. "On the basis of these encouraging data, we plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to allow us to begin human clinical trials with AT-406 later this year."

About AT-406

AT-406 is an orally-active, small molecule drug designed to promote programmed cell death (apoptosis) in tumor cells
'/>"/>

SOURCE Ascenta Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
2. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
3. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
4. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
6. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
7. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
8. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
9. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
10. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
11. Arno Therapeutics Reports 2008 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Xencor, Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... of Debra Zack , M.D., Ph.D., vice ... Lloyd Rowland , senior vice president, chief compliance ... expertise in biologics clinical development and medical affairs ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 PMG ... its 11th clinical research site: PMG Research of Rocky ... and operation of the clinical research department at ... PMG’s presence in eastern North Carolina. This new site ... the patients in Rocky Mount and the surrounding communities, ...
(Date:9/1/2014)... 1, 2014 Reportlinker.com announces that a ... catalogue: India Solid Waste Management Vehicles ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... governing bodies responsible for complete handling and regulation ... average, around 135,000 MT solid waste is generated ...
(Date:8/31/2014)... 2014 Available spectra is similar ... research and cultivation of a wide range of ... LEDs with proven patented and pending wide spectrum ... uniformity in critical applications in contrast to growth ... “Our customers have a large variety of differently ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8
... Including Launch of Key ... Bavituximab Phase II Cancer Program-, TUSTIN, Calif., March ... stage biopharmaceutical,company developing monoclonal antibodies for the treatment of cancer ... third quarter of fiscal year (FY) 2008 ended January 31, ...
... XI,AN, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- China,Bionanometer ... company,within the bionanometer industry has formally signed ... with China Guangzhou,LGLY Advertising LTD., Guangzhou ... agency. It was,founded in December 1997 and ...
... Emerging Nanotechnologies (PEN) and National Science Foundation (NSF) ... the television series Nanotechnology: The Power of Small ... onlywill include remarks by U.S. Senator Ron Wyden ... , The series three programs explore critical questions ...
Cached Biology Technology:Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 10CBIU Signs Agreement with LGLY Advertising LTD 2New nanotechnology television series does 'sweat the small stuff' 2
(Date:9/2/2014)... -- A team of University of Maryland physicists ... other scientists say make possible new nanostructures and ... energy and quantum computing advances to new sensor ... of Nature Communications the Maryland scientists, ... for hybrid nanostructures that uses a connector, or ...
(Date:9/2/2014)... a new study that could ultimately lead to many ... Scripps Research Institute (TSRI) have adapted a chemical approach ... molecules that can treat a form of muscular dystrophy. ... and a disease-causing defect as a catalyst to synthesize ... Matthew Disney.,"Because the treatment is synthesized only in diseased ...
(Date:9/2/2014)... COLUMBUS, Ohio New research suggests that professional baseball pitchers ... or more days in a single season because of injury ... their lower back and pelvis. , In the study, 347 ... with more tilt in their pelvis as they raised a ... likely to miss at least 30 days cumulative, not ...
Breaking Biology News(10 mins):New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3Scripps Florida scientists make diseased cells synthesize their own drug 2In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3
... show that summertime storms in the southeastern United States shed ... from humans is likely driving that trend. The ... evident in data from NASA,s Tropical Rainfall Measuring Mission satellite, ... more rain and span a larger area across the Southeast ...
... Stowers Institutes Trainor Lab has demonstrated the role of ... nervous system, a process that requires coordination of differentiation ... division that increases their numbers. Until now, the mechanisms ... The findings will be published in the ...
... 28, 2008 -- As organic farming becomes more ... are increasingly important. In a recent study in ... isotopic discrimination to determine if non-organic, synthetic fertilizers ... at the Instituto Murciano de Investigacin y Desarrollo ...
Cached Biology News:NASA data link pollution to rainy summer days in the southeast 2NASA data link pollution to rainy summer days in the southeast 3Trainor Lab characterizes gene essential for prenatal development of nervous system 2Is it organic or not? 2
... is designed to deparaffinize and perform Heat ... paraffin-embedded tissue sections mounted on glass microscope ... paraffin at the high temperature used in ... of the paraffin by detergent. Formaldehyde fixation ...
NEWBORN CALF SERUM AND PLASMA...
...
Synaptic Vesicle I Sampler Kit 10g each...
Biology Products: